About MBX Biosciences
MBX Biosciences is a publicly listed company based in Carmel (United States) founded in 2018. Drugs for rare endocrine diseases are developed and advanced. MBX Biosciences has raised $215.6 million across 4 funding rounds from investors including Orbimed, RA Capital and Driehaus. The company has 43 employees. Its website mbxbio.com draws about 11 thousand monthly visits. MBX Biosciences offers products and services including Canvuparatide, MBX 1416, MBX 4291, and MBX 2109. Its focus areas include Life Sciences, Rare Diseases, Drugs and Endocrine Diseases. Its legal entity is Mbx Biosciences, Inc. Its competitors include Neurocrine, Crinetics and Radionetics; 3 of its 3 listed competitors have raised funding.
Company details
MBX Biosciences is a developer of drugs for the treatment of rare endocrine diseases. It has developed endocrine drugs including Forteo and Humalog for the treatment of rare diseases. It uses use peptide hormones to regulate many physiological functions including growth, energy utilization, metabolism, gastrointestinal function, and stress responses.
- Headquarters Carmel, United States
- Employees 43
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website mbxbio.com
- Social LinkedIn
- Legal Name Mbx Biosciences, Inc.
- Net Profit-$86.97 M (USD)-40.45as on Dec 31, 2025
- EBITDA-$97.81 M (USD)-43.94as on Dec 31, 2025
- Total Equity Funding$215.6M (USD)
in 4 rounds
- Latest Funding Round$63.5M (USD), Series C
Aug 2024
- InvestorsOrbimed
& 10 more
- Employee Count43
Products & Services of MBX Biosciences
MBX Biosciences offers a comprehensive portfolio of products and services, including Canvuparatide, MBX 1416, MBX 4291, and MBX 2109.
Peptide therapy for treating endocrine disorders effectively.
Advanced treatment for metabolic conditions and related issues.
Peptide-based solution for endocrine and health management.
Innovative peptide for addressing metabolic disorders.
Funding Insights of MBX Biosciences
MBX Biosciences has successfully raised a total of $215.6M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $63.5 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $215.6M
- Total Rounds 4
- Last Round Series C — $63.5M
- First Round $2.5M
(Jun 2019)
- Investors Count 11
All 4 funding rounds of MBX Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $63.5M | Series C | – | Deep Track Capital | |
| Nov 2022 | $115M | Series B | – | Wellington | |
| Jul 2020 | $34.6M | Series A | – | Frazier Healthcare Partners | |
| Jun 2019 | $2.5M | Seed | – | IU Ventures | – |
11 investors in total: 11 institutional.
Investors in MBX Biosciences
MBX Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Healthcare investment firm focused on novel therapeutics development. | frazierls.com | Palo Alto, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Early-stage life science companies are supported through venture capital. | twivp.com | Indianapolis, United States | ||
| iuventures.com | ||||
Fund investment management services are provided by Driehaus in Chicago. | 1982 | driehaus.com | Chicago, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States |
Investor details for MBX Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MBX Biosciences
25 people are tracked at MBX Biosciences (13 in leadership, 6 in board & advisors, 6 in team); the tracked headcount is 43.
| Name | Role | Group |
|---|---|---|
Tyler Carner | Senior Director, Controller | Leadership |
Stewart Hallett | Vice President, Clinical Operations | Leadership |
Vasily Gelfanov | Sr. Scientific Director In Vitro Pharmacology | Leadership |
Mary Jane Geiger | Chief Medical Officer | Leadership |
Richard Bartram | CFO | Leadership |
Kent Hawryluk | President & CEO | Leadership |
Michelle Graham | Chief Human Resources Officer | Leadership |
Elisa Fabbrini | Vp, Clinical Development | Leadership |
Matt Gambino | VP, Marketing | Leadership |
Rachel Morrison | Director of Regulatory Affairs | Leadership |
Michael Hackett | Senior Director Of Pharmacology And Toxicology | Leadership |
Michael A. Dorato | VP, Pharmacology & Toxicology | Leadership |
Andreas G. Moraitis | Senior Vice President Clinical Development | Leadership |
Patrick Heron | Director | Board & advisors |
Ed Mathers | Director | Board & advisors |
Jim Cornelius | Director | Board & advisors |
Carl L. Gordon | Director | Board & advisors |
Ora Pescovitz | Director | Board & advisors |
Tiba Aynechi | Director | Board & advisors |
Sachi Amatya | Clinical Data Strategy And Management Leadership | Team |
5 more people are available in the full profile.
Complete people profiles for MBX Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MBX Biosciences
MBX Biosciences is a publicly listed company on the NASDAQ with ticker symbol MBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Sep 2024
- Listed onNASDAQ: MBX
- Listed entityMBX Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS55287L1017
- Share price$49.00 (-5.81% on the day) · 2026-10-13
- Market capitalisation$2.36B
- EPS (diluted, trailing year)$-2.41
- Volume (last session)768,999
Financials of MBX Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$87.0M | -$97.8M | |
| 2024 | -$61.9M | -$68.0M | |
| 2023 | -$32.6M | -$35.1M | |
| 2022 | -$26.1M | -$25.1M |
Detailed financial statements for MBX Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of MBX Biosciences
4 dated milestones of MBX Biosciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded MBX Biosciences is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series C, of $63.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of MBX Biosciences
MBX Biosciences has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and Radionetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| radionetics.com | 2021 | San Diego, United States | $136.71M | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. |
Detailed competitors of MBX Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MBX Biosciences
The website of MBX Biosciences (mbxbio.com) receives about 10.8K visits a month and ranks #2,622,411 among all websites worldwide, #3,583 in Biotechnology and Pharmaceuticals.
- Monthly visits10.8K
▲ 29.9% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,622,411
among all websites
- Category rank#3,583
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.7
- Average visit12 sec
- DevicesDesktop 47% · Mobile 53%
Top companies in Metabolic Diseases
3 companies that operate in the same segment as MBX Biosciences (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mbx Biosciences
Complete news archive for MBX Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MBX Biosciences
MBX Biosciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.
MBX Biosciences is headquartered in Carmel, United States. It is registered at Carmel, California, United States.
MBX Biosciences is a funded company, having raised a total of $215.6M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.5M, raised on Jun 2019.
MBX Biosciences has 43 employees.
MBX Biosciences is a developer of drugs for the treatment of rare endocrine diseases. It has developed endocrine drugs including Forteo and Humalog for the treatment of rare diseases. It uses use peptide hormones to regulate many physiological functions including growth, energy utilization, metabolism, gastrointestinal function, and stress responses.
MBX Biosciences's top competitors include Crinetics, Neurocrine and Radionetics.
MBX Biosciences offers Canvuparatide, MBX 1416, MBX 4291, and MBX 2109.
Yes, MBX Biosciences is publicly traded on NASDAQ under the ticker symbol MBX.
MBX Biosciences has 11 investors. Key investors include Orbimed, RA Capital, Driehaus, Norwest Venture Partners, and Frazier Healthcare Partners.
MBX Biosciences operates through Mbx Biosciences, Inc..